Su Wang

Dr. Su Wang


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 April 2023 in Frontiers in Public Health
Verified
Journal Article
Open access
JZJialin Zhu
Jialin Zhu
YTYaning Tang
Yaning Tang
YWYanyi Wei
Yanyi Wei
SWSu Wang
Su Wang
YCYuwen Chen
Yuwen Chen
The relationship between financialization and innovation has become a common focus of academic attention. This paper analyzes the influence of corporate financialization on innovation efficiency based on balanced panel data of listed Chinese pharmaceutical companies from 2015 to 2020. Also, it examines the relationship between corporate financialization and innovation efficiency under different levels of financing constraints and the moderating mechanisms that exist. The results of the study show that corporate financialization negatively affects innovation efficiency and that this effect has a lag; corporate financialization hurts innovation efficiency across the different regions and firm nature, with a less inhibiting effect for eastern firms and non-state-owned firms; further tests of the mechanism of action show that there is a non-linear negative relationship between corporate financialization and innovation efficiency. And the inhibition of corporate financialization on innovation efficiency decreases as the level of financing constraints rises. Based on the above findings, this study provides warnings and recommendations for pharmaceutical companies to finance their innovative activities through financialization.

23 November 2023 in Therapeutic Innovation & Regulatory Science
Verified
Journal Article
Open access
PDF file
PLPei Li
Pei Li
SWSu Wang
Su Wang
YCYuwen Chen
Yuwen Chen
Traditional Chinese medicine (TCM) is a valuable resource unique to China with a long history of human use and clinical practice, which can be analyzed to generate real-world evidence (RWE). The Chinese government has been actively promoting regulatory reform that is in line with the characteristics of TCM, optimizing the clinical evidence system for TCM, and exploring the important role of RWE in supporting the development of new drugs and regulatory decision-making for TCM. This article aims to provide a comprehensive review of the use of RWE in regulatory decisions for TCM. Based on the characteristics of TCM, this study focuses on the application scenarios, challenges, and opportunities of RWE in TCM. And some suggestions are put forward to promote the wider application of RWE in TCM development and supervision.

3 July 2024 in Frontiers in Public Health
Verified
Journal Article
Open access
PDF file
XCXinqing Chen
Xinqing Chen
SCShiyi Chen
Shiyi Chen
ZWZikun Wu
Zikun Wu
SWSu Wang
Su Wang
YCYuwen Chen
Yuwen Chen
In 2018, China began to gradually promote the pilot policy of centralized band purchasing of medicines. Implementing this policy has resulted in a significant decrease in drug prices. However, there needs to be a clear consensus on the impact and mechanism of action on the innovation of pharmaceutical companies. Therefore. Taking the data of Chinese Shanghai and Shenzhen A-share pharmaceutical listed companies from 2016 to 2022 as a sample, this paper empirically investigates the impact of the centralized banded purchasing policy of drugs on the innovation of pharmaceutical enterprises by using a double difference model and further analyzes the mechanism of its action. The results show that implementing the centralized banded purchasing policy can promote pharmaceutical enterprises’ innovation input and output, which is robust under the parallel trend and placebo tests. Further exploring the impact mechanism of the centralized band purchasing policy on pharmaceutical enterprises’ innovation, it can be found that it promotes innovation inputs through three channels: government subsidies, enterprise profits, and operating income. In addition, the impact of centralized band purchasing on enterprise innovation is heterogeneous in terms of region, enterprise nature, and scale. Therefore, the positive effects of the centralized band purchasing policy on promoting innovation in pharmaceutical enterprises should be fully recognized, and enterprise heterogeneity should be taken into account when implementing the policy. This study provides empirical evidence on the implementation effect of the centralized banded purchasing policy and provides lessons for continuously optimizing the policy to promote the high-quality development of pharmaceutical enterprises.

4 November 2025 in PLOS ONE
Verified
Journal Article
Open access
LLLiqiang Li
Liqiang Li
SWSu Wang
Su Wang
YCYuwen Chen
Yuwen Chen
Environmental, social and governance performance is an important driver for companies to achieve innovative and high-quality development, and the relationship between sustainable development and corporate innovation is one of the key concerns of pharmaceutical companies. This study aims to reveal the intrinsic role mechanism of sustainable transformation of pharmaceutical enterprises in high-quality innovation development. Based on the relevant data of China’s A-share pharmaceutical listed companies from 2015 to 2022, the study establishes a fixed effect model and a mediation effect model, empirically examines the impact of ESG performance on the innovation of pharmaceutical listed companies, and deeply explores the role mechanism of R&D personnel investment and government subsidies in it. The study finds that: (1) ESG performance significantly enhances firms’ innovation inputs and green innovation outputs; (2) this facilitating effect is more substantial among non-state-owned firms and firms in the eastern region; (3) good ESG performance has a more pronounced facilitating effect on innovation inputs of large firms, while it has a more prominent effect on the green innovation outputs of small and medium-sized firms; and (4) the mechanism analysis indicates that internal R&D personnel investment and external government subsidies play a significant mediating effect between ESG performance and corporate innovation. This study provides new empirical evidence for understanding the mechanism of ESG performance on corporate innovation in Chinese pharmaceutical companies. It provides theoretical support for proactively promoting the sustainable transformation and deepening the development of green innovation in Chinese pharmaceutical companies. In addition, there are important policy implications for promoting the sustainable transformation of pharmaceutical companies: the establishment of differentiated ESG incentive policies, the improvement of R&D talent training mechanisms, and the optimization of government subsidy allocations, focusing on supporting green innovation by companies with excellent ESG performance.

9 April 2025 in Frontiers in Public Health
Verified
Journal Article
Open access
PDF file
XZXyv Zhao
Xyv Zhao
SWSu Wang
Su Wang
YCYuwen Chen
Yuwen Chen
Digital inclusive finance, with ‘universality’ as its core feature, can stimulate enterprises to increase capital investment in research and development (R&D) through diversified channels. Using the digital financial inclusion index of 337 prefecture-level cities in China and the empirical data of Shanghai and Shenzhen A-share-listed pharmaceutical manufacturing enterprises from 2011 to 2022, the article empirically examines the impact mechanism of digital financial inclusion on R&D investment of pharmaceutical manufacturing enterprises from the perspective of government subsidy by using a high-dimensional fixed-effects model, a two-stage systematic GMM, and a moderated-effects test method. It is found that digital financial inclusion has a positive incentive effect on pharmaceutical manufacturing enterprises to increase R&D investment, and this positive effect still holds after the endogeneity test and robustness test. The results of the moderating effect test indicate that government subsidies play a positive moderating role in the process of digital financial inclusion affecting enterprises’ R&D investment. Further analyses show that digital financial inclusion has a more significant role in promoting the intensity of R&D investment in pharmaceutical enterprises in private enterprises, small and medium-sized enterprises, and regions with lower levels of traditional financial development. Finally, policy suggestions are put forward according to the conclusion. Including the government to promote digital infrastructure and policy support, financial institutions to build data platforms to support pharmaceutical innovation, and enterprises to increase investment in research and development and expand financing channels to jointly promote the transformation and upgrading of the industry.

3 January 2025 in Frontiers in Public Health
Verified
Journal Article
Open access
PDF file
JLJiawen Li
Jiawen Li
XZXingyu Zhao
Xingyu Zhao
SWSu Wang
Su Wang
YCYuwen Chen
Yuwen Chen
Enterprise innovation investment is influenced by the actions of innovation subjects, whereas regulating shareholders’ equity pledge behavior facilitates innovation investment and finance but also carries dangers and affects enterprise innovation investment. Methods:This paper builds an unbalanced panel model to empirically analyze the impact of controlling shareholders’ equity pledges on corporate innovation and its heterogeneous characteristics. It also looks at the moderating role of corporate financing constraints and the mediating role of equity incentives, using data from A-share listed companies in China’s pharmaceutical manufacturing industry from 2015 to 2022. Innovation investment is substantially inversely correlated with controlling shareholders’ equity pledge; that is, firms’ creative behavior and intensity are inhibited by equity pledge. Results and conclusions:The results also show that controlling shareholders’ equity commitments have a more pronounced negative impact on enterprises’ ability to innovate than non-state-owned and decentralized equity firms. The relationship between company innovation and the equity pledge of controlling shareholders is somewhat mediated by equity incentives. The relationship between controlling shareholders’ equity promises and enterprises’ innovation is negatively moderated by financing limitations, which also reduces R&D expenditure and stifles innovation.